Related references
Note: Only part of the references are listed.Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface
Nami Masubuchi et al.
LEUKEMIA (2020)
Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development
Thomas Balligand et al.
LEUKEMIA (2020)
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms
Christian A. Di Buduo et al.
BLOOD (2020)
Both sides now: losses and gains of mutant CALR
Ann Mullally
BLOOD (2020)
Calnexin cycle - structural features of the ER chaperone system
Guennadi Kozlov et al.
FEBS JOURNAL (2020)
Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN
Camelia Benlabiod et al.
NATURE COMMUNICATIONS (2020)
Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
Kasper Monsted Pedersen et al.
ECLINICALMEDICINE (2020)
Interleukin-6: A Masterplayer in the Cytokine Network
Peter Uciechowski et al.
ONCOLOGY (2020)
Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study
Kasper Monsted Pedersen et al.
ECLINICALMEDICINE (2020)
AKT activation is a feature of CALR mutant myeloproliferative neoplasms
Chunling Fu et al.
LEUKEMIA (2019)
Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants
Christian Pecquet et al.
BLOOD (2019)
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
Maria Kleppe et al.
CANCER CELL (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Simon A. Jones et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stemcell self-renewal advantage
Juan Li et al.
BLOOD (2018)
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Targeting the CALR interactome in myeloproliferative neoplasms
Elodie Pronier et al.
JCI INSIGHT (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation
K. Kollmann et al.
LEUKEMIA (2017)
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
D. T. Saenz et al.
LEUKEMIA (2017)
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis
Paola Guglielmelli et al.
BLOOD (2017)
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
Ilyas Chachoua et al.
BLOOD (2016)
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
Caroline Marty et al.
BLOOD (2016)
Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis
Paola Guglielmelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency
Alexandre P. A. Theocharides et al.
BLOOD (2016)
Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets
Xiuli Sim et al.
BLOOD (2016)
Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin
T. Balligand et al.
LEUKEMIA (2016)
Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly
Daria Sollazzo et al.
MEDIATORS OF INFLAMMATION (2016)
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
Shannon Elf et al.
CANCER DISCOVERY (2016)
Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells
Robert S. Welner et al.
CANCER CELL (2015)
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
P. Guglielmelli et al.
BLOOD CANCER JOURNAL (2015)
JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Maria Kleppe et al.
CANCER DISCOVERY (2015)
Functional Roles of Calreticulin in Cancer Biology
Yi-Chien Lu et al.
BIOMED RESEARCH INTERNATIONAL (2015)
MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling
K. Kollmann et al.
LEUKEMIA (2015)
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno et al.
BLOOD (2014)
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Elisa Rumi et al.
BLOOD (2014)
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
Ayalew Tefferi et al.
BLOOD (2014)
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
A. M. Vannucchi et al.
LEUKEMIA (2014)
Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact
A. Tefferi et al.
LEUKEMIA (2014)
JAK Inhibitor in CALR-Mutant Myelofibrosis
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis
Qing Chang et al.
NEOPLASIA (2013)
NF-κB and STAT3 cooperatively induce IL6 in starved cancer cells
S. Yoon et al.
ONCOGENE (2012)
Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis
Xiaoping Zhang et al.
Expert Review of Clinical Pharmacology (2011)
Calreticulin: non-endoplasmic reticulum functions in physiology and disease
Leslie I. Gold et al.
FASEB JOURNAL (2010)
Share Paper
